StockpollyBeta
Get App
Delisting riskPopularity #4,824
NDRA · NASDAQ · Medical - Diagnostics & Research

ENDRA Life Sciences (NDRA)

Developing radio-frequency thermoacoustic ultrasound for point-of-care liver-fat measurement.

$6.47
vs last close+0.24 (+3.85%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
313224111221
Research & development211111100110
112214111111
Selling & marketing000000000000
General & administrative112114111111
Other expenses000000000000
Operating income−3−1−3−2−2−4−1−1−1−2−2−1
0000−10000−212
Interest expense000070000000
Other non-operating income0000−600002−10
Income before tax−3−1−3−2−2−4−1−1−2−3−10
Net income from continuing operations−3−1−3−2−2−4−1−1−2−3−10
Net income−3−1−3−2−2−4−1−1−2−3−10
EPS, basic−$1.82−$0.85−$1.63−$1.31−$2.10−$7.73−$1.86−$1.71−$2.10−$3.26−$1.09$0.12
EPS, diluted−$1.82−$0.85−$1.63−$1.31−$2.10−$7.73−$1.86−$1.71−$2.10−$3.26−$1.09$0.06
Weighted average shares, basic222211111111
Weighted average shares, diluted222211111112
EBITDA−3−1−3−25−4−1−1−2−3−1−1
Depreciation & amortization000000000000
EBIT−3−1−3−25−4−1−1−2−3−1−1